BNT324 vs Docetaxel for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicines prednisone or prednisolone). The study will include participants with mCRPC that have been previously treated with androgen receptor pathway inhibitor, but with no previous taxane-based systematic chemotherapy for mCRPC.
The main goals of this study are:
* To find out if BNT324 helps participants live longer without their cancer getting worse (radiographic progression-free survival \[rPFS\]).
* To find out if BNT324 helps participants live longer overall (overall survival \[OS\]).
Who Is on the Research Team?
BioNTech Responsible Person
Principal Investigator
BioNTech SE
Are You a Good Fit for This Trial?
Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- BNT324
- Docetaxel
- Prednisone/prednisolone
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Find a Clinic Near You
Who Is Running the Clinical Trial?
BioNTech SE
Lead Sponsor
Prof. Dr. Ugur Sahin
BioNTech SE
Chief Executive Officer since 2008
MD from University of Cologne
Prof. Özlem Türeci
BioNTech SE
Chief Medical Officer since 2018
MD from Saarland University
BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Industry Sponsor
DualityBio Inc.
Industry Sponsor
BioNTech Shanghai Pharmaceutical Co., Ltd.
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.